Eighteen plaintiffs seeking nationwide class certification may proceed with their suit alleging that Monat hair-care products, deceptively advertised as anti-aging solutions, actually cause hair loss. A US district judge on 23 October largely denied Monat’s motion to dismiss, while noting that plaintiffs may have difficulty proving that the company’s products are to blame for their injuries.
Monat Global Corp. remains optimistic about its ability to defeat a proposed class action in Florida federal court regarding the marketing and safety of its anti-aging hair-care products, despite largely failing to dismiss the suit on 23 October.
“This is just a small part of a lengthy legal process. We look forward to taking discovery, including depositions of...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
